Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma 

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Jairam Krishnamurthy, MD, FACP, details what to take into consideration when implementing 2024 Breast Cancer NCCN guideline changes into everyday practice. 

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.

Long-Term Findings Solidify Role of HER2-Targeted Therapy in Early HER2+ Breast Cancer

Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the role of RNA and the formation of liquid droplet structures within cancer cells.

Fox Chase Cancer Center Researcher Lu Chen Receives $250,000 NIH Grant to Further Investigation of RNA

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

Video Series

Clinical

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Videos

Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.

Funding supported by Taiho Oncology. Content independently developed by OncLive.

John Strickler, MD, introduces a panel of medical experts who will provide key insights for considerations in the 3L colorectal cancer treatment setting.

Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.

Selecting Optimal 3L Colorectal Cancer Treatment

Medical experts dissect the first patient-specific case and corresponding treatment regimen.

Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Treatment Considerations With Regorafenib in Colorectal Cancer

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.

Monitoring and AE Management Strategies with Fruquintinib in CRC

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Toxicity Considerations and Treatment Decisions in CRC

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Multidisciplinary Care for Patients with CRC

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Latest Conference Coverage